Differential impact of two doses of antithymocyte globulin conditioning on lymphocyte recovery upon haploidentical hematopoietic stem cell transplantation

Table 1 Clinical characteristic of patients

	ATG-6	ATG-10	P value
Subjects, n	29	31
Age, years, median (range)	22 (16–48)	29 (15–48)	0.11
Gender, n (%)
Male	18 (62.1)	24 (77.4)	0.19
Female	11 (37.9)	7 (22.6)
Diagnosis, n (%)
AML	12 (41.4)	14 (45.2)	0.77
ALL	12 (41.4)	12 (38.7)
CML	2 (6.9)	3 (9.6)
MDS (RAEB)	3 (10.3)	2 (6.5)
CD34⁺ cells in graft, ×10⁶/kg, median (range)	2.4 (0.7–4.9)	3.1 (0.3–7.8)	0.32
Donor type	Related donors
HLA typing	1–3/6 Mismatch
Stem cell source	BM + PB
Conditioning regimen	BU + CY + ATG
GVHD prophylaxis	CSA + MMF + MTX

ATG antithymocyte globulin, AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, BM bone marrow, BU busulfan, CML chronic myeloid leukemia, CSA cyclosporine A, CY cyclophosphamide, HSCT hematopoietic stem cell transplantation, MDS myelodysplastic syndrome, MMF mycophenolate mofetil, MTX methotrexate, PB peripheral blood

ISSN: 1479-5876